Three items are still in play for the remainder of 2026: the OMB proposed rule, the permitting bill, and Senate confirmations.
By Irene Ngun, Director of Science Policy and Advocacy, Stand Up for Science Foundation
While the scientific community looks ahead to a new year and a newly empowered Congress, the final weeks of 2026 remain precarious. Decisions made or left unresolved in this period will shape the research enterprise for years. Here are three key things we are watching over the next several weeks:
1. OMB proposed rule
On December 11, the continuing resolution that currently funds the federal government will expire. That deadline will also lift the temporary pause Congress imposed on the Office of Management and Budget’s proposed overhaul of the rules governing federal grants. Despite the pause, a number of agencies have already begun incorporating elements of the still-unfinalized rule into their own policies, funding announcements, and award terms. These include political pre-review of awards, broader authority to terminate projects, new restrictions on international collaboration, and criteria linked to “Gold Standard Science.”
The December 11 deadline therefore raises two questions. The first is whether OMB will be allowed to finalize the regulation. The second is whether the next funding bill will extend the existing block and close the loophole that has permitted agencies to move forward on their own. Public comments and congressional pressure have slowed some of these efforts. The National Science Foundation, for example, has scaled back certain explicit alignments in its revised Guidance for Financial Assistance. Other agencies have been less forthcoming.
In the meantime, active grants, pending awards, clinical trials, international collaborations, and the careers of early-stage researchers remain exposed. Even if the full rule never takes effect, the process has already been disrupted in ways that have reduced transparency and certainty. Restoring a system in which scientific merit, rather than political preference, determines what gets funded will be one of the more straightforward tasks facing the next Congress. Undoing the interference will require deliberate work.
2. Senate votes for science agency leadership
Senate Republicans are moving to confirm as many nominees as possible before Democrats take the majority in January. Several science agencies are facing leadership transitions at the same time. At the National Science Foundation, which has gone more than a year and a half without a confirmed director, Acting Director Brian Stone is retiring at the end of the year. The nomination of James O’Neill is advancing toward a committee vote next week on November 18. O’Neill, a favorite among the tech right, with long-standing ties to Peter Thiel’s network and Silicon Valley, would be the first non-scientist to lead the agency.
What this nomination reflects is another deliberate effort to let the tech right set the direction of the federal science agenda. O’Neill comes out of venture capital and the policy circles that have advocated a tighter focus on AI, quantum, and commercially driven priorities, rather than from science or science administration. Placing him at NSF would solidify that influence into the agency responsible for funding fundamental research across fields. If O’Neill is confirmed, the priorities of the science and research ecosystem will continue to be shaped by a small network of tech right groups rather than by the broader scientific community the agency was built to serve.
The Senate is also scheduled to vote on Heidi Overton to lead the FDA. She had her confirmation hearing last month. As commissioner, Overton would oversee an agency with roughly 16,000 staff and a $7 billion annual budget—and inherit an agency that has seen unprecedented disruptions to its operations with about 4,600 workers lost through reductions in force since 2024.
3. The bipartisan permitting bill (BAAJA)
Finally, the Senate is advancing the Bipartisan American Affordability and Jobs Act, a major permitting overhaul negotiated by leaders of both parties’ energy and environment committees. The White House is pushing it as a lame-duck priority. It would set tighter timelines for environmental reviews, expand federal authority over interstate transmission, and limit the window for legal challenges. This is one of the last chances for the current Congress to lock in energy and infrastructure rules before the new Democratic majorities take office. Modeling shows potential benefits for clean energy deployment and grid expansion, but environmental groups have warned that it also accelerates fossil projects and provides little to no guardrails for further data center builds amid nation-wide data center pushback. Science infrastructure, climate research sites, and energy-related research facilities can be affected either way.
Permitting rules shape where and how quickly energy projects, research facilities, and climate-related infrastructure can be built. The deal that passes now will be hard to undo down the line.
Final Thoughts
The remainder of 2026 is short, but the decisions still in play are not minor. Whether the OMB block is extended, whether the permitting deal passes, and who is confirmed to lead key science agencies will define the starting point for the next Congress. The scientific community does not have to wait until January to have a say in those outcomes.